Resonance Health (ASX:RHT) Shares Preliminary Liver Fibrosis Study Results

Aditi Sarkar

27 October 2026 07:36 PM AEDT

Resonance Health (ASX:RHT) Shares Preliminary Liver Fibrosis Study Results

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

$6.0 million institutional placement at 7.2 cents per share, led by Bell Potter.
FY26 revenue rose 42% to $15.8 million, with statutory NPAT of $1.5 million.
Preliminary fibrosis study showed an AUC of 0.820 for significant fibrosis.
FY27 guidance of $17 to $22 million revenue and $2.6 to $3.6 million EBITDA.

Resonance Health Ltd (ASX:RHT) has released a capital raising presentation for a $6.0 million institutional placement, along with preliminary results from its extended proof-of-concept (EPoC) liver fibrosis study. The placement is priced at 7.2 cents per share, and Bell Potter Securities is lead manager.

Placement Terms and Use of Funds

About 83.3 million new shares will be issued, representing 14.9% of enlarged capital. The price is a 12.2% discount to the last close of 8.2 cents. New shares are expected to be allotted on 9 November 2026, and no shareholder approval is required.

The funds will support MRI endpoint development ($1.2 million), expansion of the TrialsWest clinical trial network to the east coast ($1.5 million), the liver fibrosis device program ($1.5 million) and working capital ($1.4 million). Pro forma cash after the placement is $10.4 million.

FY26 Results and FY27 Guidance

Revenue for the year ended 30 June 2026 rose 42% to $15.8 million. Normalised EBITDA was $2.6 million, statutory NPAT was $1.5 million, and operating cash flow was positive in all four quarters.

For FY27, Resonance is guiding revenue of $17 to $22 million and EBITDA of $2.6 to $3.6 million. This guidance excludes fibrosis device revenue, acquisitions and new sites.

Preliminary Liver Fibrosis Results

An interim analysis of 50 of 68 enrolled subjects, from a single site in China, showed an AUC of 0.820 for significant fibrosis (F2 or above), with 75.0% sensitivity and 80.0% specificity. For advanced fibrosis (F3 or above), the AUC was 0.788.

The company noted the results are preliminary, have not been independently verified and come from a small cohort with wide confidence intervals. The device is investigational and is not cleared for clinical use. Next steps include completing the full study and an FDA Pre-Submission.

Key Takeaways

The $6.0 million placement strengthens Resonance's balance sheet for growth programs.
FY26 revenue growth was supported by all three business segments.
Early fibrosis results are encouraging but remain preliminary.
Key upcoming steps include the full EPoC analysis and FDA feedback.

FAQs

Q: How much is Resonance Health raising?

A: Resonance is raising $6.0 million through an institutional placement.

Q: What is the placement price?

A: The placement is priced at 7.2 cents per share.

Q: What was FY26 revenue?

A: Revenue rose 42% to $15.8 million.

Q: What is the FY27 revenue guidance?

A: Resonance is guiding revenue of $17 to $22 million.

Q: Is the fibrosis device approved?

A: No. The device is investigational and is not cleared for clinical use in any jurisdiction.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.